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The CXC chemokines are a family of closely related chemoat-
tractant cytokines that bind to, attract, and activate neutrophils
to variable degrees. In this study, the relationship between
neutrophil-binding affinity and suitability for infection imaging
was investigated in a selected group of CXC chemokines. Neu-
trophil–activating peptide-2 (NAP-2, 70 residues; also called
CXCL7) binds with high affinity to the CXCR2 receptor on neu-
trophils. Recently, C-terminally truncated NAP-2-variants have
been described that have enhanced neutrophil-binding affinity
and neutrophil-stimulating capacity. Here, NAP-2 and its
C-terminal shortened variants NAP-2(1–68), NAP-2(1–66), and
NAP-2(1–63) were labeled with 99mTc via the hydrazinonicoti-
namide (HYNIC) chelator and their potential for imaging of in-
fection was investigated in a rabbit model of infection. The CXC
chemokine interleukin-8 (IL-8) was used for comparison. In
addition, a series of 99mTc-labeled CXC chemokines were
screened for their potential to image infection, including CTAP-
III, GCP-2, ENA-78, PF-4, and IP-10. Methods: The receptor-
binding affinity of HYNIC-conjugated NAP-2 and its analogs
was compared in competitive binding assays on Jurkat cells
transfected with the CXCR2 receptor gene. Biodistribution of
labeled NAP-2 (analogs) and other CXC chemokines in rabbits
with intramuscular Escherichia coli infections was determined
both by -camera imaging and by counting dissected tissues at
6 h after injection. Results: The CXCR2-binding affinity of the
HYNIC-conjugated NAP-2 analogs relative to NAP-2 was as
follows: NAP-2(1–68), 2.5-fold; NAP-2(1–66), 10-fold; and NAP-
2(1–63), 3-fold. In the rabbit model, uptake in the abscess (in
percentage injected dose per gram  SEM) was 0.084  0.015
for NAP-2, 0.098  0.010 for NAP-2(1–68), 0.189  0.044 for
NAP-2(1–66), and 0.114  0.017 for NAP-2(1–63) at 6 h after
injection. In comparison, higher uptake in the abscess was
found for labeled IL-8, a modest uptake was found for GCP-2
and ENA-78, and a low uptake was found for CTAP-III, PF-4,
and IP-10. Conclusion: This study showed a clear relationship
between affinity to receptors on neutrophils and suitability for
infection imaging. Of the NAP-2 variants, NAP-2(1–66) com-
bined highest affinity to CXCR2 with the best characteristics for
imaging. IL-8 binds to both CXCR1 and CXCR2 with high affinity
and showed a superior imaging quality. The other CXC chemo-
kines tested bind to neutrophils with lower affinity and were
shown to be less suitable for infection imaging in this study.
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White blood cells, particularly neutrophils and mono-
cytes, accumulate in high numbers at sites of infection.
They function as the primary line of defense in the destruc-
tion of microorganisms and initiate the repair of tissue. A
variety of chemotactic peptides and proteins orchestrate the
directed migration of leukocytes to inflammatory sites. Po-
tentially, these leukocyte-binding proteins can be used as an
infection imaging agent, labeled either in their original
natural form or in the sophisticated disguise of a receptor
antagonist (1). This study focuses on a selection of chemo-
kines for infection imaging.
The chemokines (short for chemoattractant cytokines) are
a superfamily of closely related cytokines. Most of the
chemokines are small, with molecular weights in the range
of 8–12 kDa. The chemokine superfamily is divided into
subfamilies depending on the position of the highly con-
served cysteines (2). One major subfamily is designated
“CXC” because the 2 cysteines (C) nearest the N-termini of
these proteins are separated by a single, nonconserved
amino acid residue (X). The other major subfamily is called
“CC” because these 2 cysteines are adjacent. The CXC
chemokines act predominantly on neutrophils, whereas the
CC chemokines act on lymphocytes, monocytes, mast cells,
and eosinophils (3). The CXC chemokine subfamily can be
further divided into ELR and ELR CXC chemokines
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depending on the presence or absence of a Glu-Leu-Arg
(ELR) motif, respectively. This motif is positioned in the
NH2-terminal region just in front of the first cysteine of the
CXC motif. The ELR CXC chemokines are the most
selective chemotactic factors for neutrophil migration. In-
terleukin-8 (IL-8; recently renamed CXC chemokine ligand
8 [CXCL8] (4)) is the prototype of this group and is the
most potent neutrophil-activating protein of the CXC
chemokines in the human system (2,5,6). Other members
of this group include growth-regulated oncogene (GRO
[CXCL1], GRO [CXCL2], and GRO ([CXCL3]), con-
nective tissue–activating peptide-III (CTAP-III), neutro-
phil- activating protein-2 (NAP-2 [CXCL7]), epithelial
cell–derived neutrophil attractant-78 (ENA-78 [CXCL5]),
and granulocyte chemotactic protein-2 (GCP-2 [CXCL6]).
The ELR CXC chemokines include platelet factor-4
(PF-4 [CXCL4]) and interferon-–inducible protein (IP-10
[CXCL10]).
There are 2 high-affinity G protein-coupled CXC chemo-
kine receptors on neutrophils: CXC chemokine receptor 1
(CXCR1) and CXCR2 (7). IL-8 and GCP-2 bind to both
CXCR1 and CXCR2, whereas the other ELR CXC che-
mokines are specific ligands for CXCR2 (8,9). The ELR
CXC chemokines PF-4 and IP-10 lack significant CXCR1
and CXCR2 binding (10,11). PF-4 is reported to be active
on many different cell types, including neutrophils (12), but
no G protein–coupled receptor has been identified for PF-4
so far.
In this study, we aimed to select the most promising
candidates within the family of the CXC chemokines. Is
there a clear relationship between biologic properties such
as neutrophil chemoattractant activity (as can be assessed in
Boyden chamber assays), neutrophil-activating properties
(e.g., elastase release), and neutrophil-binding affinity on
the one side and suitability for infection imaging on the
other side? We hypothesize that neutrophil-binding affinity
is a useful criterion for selecting the most suitable CXC
chemokine for infection imaging. This study focuses on
NAP-2 and 3 C-terminally truncated NAP-2 variants.
NAP-2 is a member of a group of CXC chemokines collec-
tively termed -thromboglobulins (12). These are platelet
-granule–derived proteins, which differ only in the length
of the termini. Platelet basic protein ([PBP] 94 residues) and
CTAP-III (85 residues) were shown to become converted
into NAP-2 (70 residues) by N-terminal truncation through
limited proteolysis (13,14). Although structurally closely
related, the -thromboglobulins PBP and CTAP-III do not
exhibit neutrophil-stimulatory activity in contrast to their
proteolytic daughter compound NAP-2. Recently, C-termi-
nally truncated NAP-2-variants have been described that
have enhanced affinity for receptors on neutrophils and
enhanced neutrophil-stimulating capacity (15,16). NAP-
2(1–68) is also named thrombocidin-1 (TC-1) and has bac-
tericidal properties (17). Here, NAP-2 and its C-terminally
shortened variants NAP-2(1–68), NAP-2(1–66), and NAP-
2(1–63) were labeled with 99mTc and their potential for
imaging infection was investigated in rabbits with intramus-
cular Escherichia coli infection. IL-8, binding to both
CXCR1 and CXCR2 with high affinity, has already been
studied in detail for infection imaging purposes and was
used for comparison (18–20).
In addition, a broad inventory of the CXC chemokines for
infection imaging was made. CTAP-III, GCP-2, and
ENA-78 (ELR CXC chemokines) and PF-4 and IP-10
(ELR CXC chemokines) are a representative selection of
the CXC chemokines that were tested in our laboratory




The following human recombinant proteins were used: NAP-2
was purchased from RDI. NAP-2(1–68), NAP-2(1–66), and NAP-
2(1–63) were produced by recombinant methods as described
previously (12). IL-8 was kindly provided by Dr. Ivan Lindley
(Novartis). GCP-2, ENA-78, and IP-10 were purchased from RDI.
CTAP-III and PF-4 were kindly provided by Dr. Alfred Waltz
(Theodor-Kocher Institute, University of Bern, Bern, Switzerland).
Conjugation of Hydrazinonicotinamide (HYNIC) to
Chemokine
The propylaldehyde hydrazone of succinimidyl-hydrazinonico-
tinamide (HYNIC) was synthesized essentially as described pre-
viously (3,21). The HYNIC-chemokine conjugate was prepared as
described previously (18). Briefly, in a 1.5-mL vial, 5 L of 1
mol/L NaHCO3, pH 8.2, was added to 35 L of chemokine (5
mg/mL). Subsequently, a 3-fold molar excess of HYNIC in 5 L
of dry dimethyl sulfoxide was added dropwise to the mixture.
After incubation for 10–30 min at room temperature, the reaction
was stopped by adding an excess of glycine (200 L, 1 mol/L in
phosphate-buffered saline [PBS]). To remove excess unbound
HYNIC, the mixture was extensively dialyzed against PBS (0.1- to
0.5-mL dialysis cell, 3.5-kDa molecular weight cutoff; Pierce).
Dialyzed samples of about 8 g HYNIC-conjugated chemokine
were stored at 20°C.
99mTc Labeling of HYNIC-Conjugated Chemokine
Tricine (N-[Tris(hydroxymethyl)methyl]glycine) was purchased
from Fluka and nicotinic acid was from Sigma-Aldrich. For labeling
of the HYNIC-conjugated chemokines with 99mTc, tricine and
nicotinic acid were used as coligands as described previously (19).
To a thawed sample of 8 g of HYNIC-chemokine was added 0.2
mL of a solution of tricine and nicotinic acid (125 and 12.5
mg/mL, respectively, in PBS, adjusted to pH 7.0 with 2 mol/L
NaOH), 20 L of a freshly prepared tin(II) solution (10 mg SnSO4
in 10 mL of nitrogen-purged 0.1N HCl), and 300–400 MBq
99mTcO4 in saline. The mixture was incubated at 70°C for 30 min.
The radiochemical purity was determined by instant thin-layer
chromatography (ITLC) on ITLC-SG strips (Gelman Laboratories)
with 0.1 mol/L citrate, pH 6.0, as the mobile phase. In case of a
labeling efficiency of 96%, the reaction mixture was applied to
a Sephadex G-25 column (PD-10; Pharmacia) and eluted with
PBS/0.5% bovine serum albumin (BSA) to purify the radiolabeled
chemokine. For animal experiments, the reaction mixture was
diluted with PBS/0.5% BSA to a concentration of 40 MBq/mL,
ready for intravenous administration in the rabbits.
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Receptor-Binding Competition Assays
The interaction of HYNIC-conjugated NAP-2, its variants, and
IL-8 with chemokine receptor CXCR2 was investigated in binding
competition assays using a single concentration of 99mTc-labeled
IL-8 and increasing concentrations of the unlabeled chemokines.
These assays were performed using Jurkat cells transfected with
the CXCR2 receptor, a kind gift of Drs. Pius Loetscher and Marco
Baggiolini (Theodor Kocher Institute, University of Bern, Bern,
Switzerland) (22). The Jurkat cells were cultured at 37°C in a
humidified atmosphere of 95% air/5% CO2 in RPMI 1640 medium
(GIBCO) containing 10% fetal calf serum and 1% glutamine,
amino acids, and pyruvate. The medium also contained penicillin/
streptomycin, 5 	 105 mol/L -mercaptoethanol, and 1.5 g/mL
puromycin for selection. Live Jurkat cells were centrifuged (5 min,
2,000g) and washed once with assay buffer (RPMI 1640, 0.5%
BSA, 0.05% NaN3). For the receptor-binding competition assays,
CXCR2-bearing Jurkat cells were suspended at
4	 108 cells per
milliliter (final concentration) in RPMI 1640 medium containing
0.5% BSA. Duplicate samples of 
2 	 108 cells were incubated
on ice for 3 h with a constant amount of 99mTc-labeled IL-8
(
0.014 nmol/L IL-8,
50,000 counts of radioactivity) as a tracer,
in the presence or absence of increasing concentrations (0.25–400
nmol/L) of HYNIC-conjugated NAP-2, its variants, and IL-8 in a
total volume of 0.5 mL. To correct for nonspecific binding of
99mTc-labeled IL-8, a sample was incubated in the presence of a
30,000-fold excess of native IL-8. After a 3-h incubation on ice,
cells were centrifuged (5 min, 2,000g) and washed twice with
incubation buffer, and the radioactivity in the pellet (total bound
radioactivity) was measured in a shielded well-type -counter
(Wizard; Pharmacia). Nonspecific binding of 99mTc-labeled IL-8
was subtracted. Each assay was performed in duplicate. The con-
centration of HYNIC-conjugated NAP-2 that caused 50% dis-
placement was set at 1 and the 50% inhibitory concentrations of
the HYNIC-conjugated NAP-2 variants and IL-8 were expressed
relative to that of HYNIC-conjugated NAP-2.
Animal Studies
For a direct comparison between 99mTc-labeled NAP-2, its 3
C-terminally truncated variants, and IL-8 in imaging intramuscular
infection, abscesses were induced in the left thigh muscle of 25
female New Zealand White rabbits (2.4–2.7 kg) with 1–2 	 1011
colony-forming units (cfu) of E. coli in 0.5 mL. During the
procedure, rabbits were anesthetized with a subcutaneous injection
of a 0.6-mL mixture of fentanyl (0.315 mg/mL) and fluanisone (10
mg/mL) (Hypnorm; Janssens Pharmaceutical). The rabbits were
divided into 5 groups of 5 animals each (5 animals per 99mTc-
labeled chemokine). After 24 h, when swelling of the muscle was
apparent, the rabbits were injected with 20 MBq 99mTc-labeled
chemokine (protein dose, 0.5 g) via the ear vein. Three rabbits
from each group were used for -camera imaging. These rabbits
were immobilized, placed prone on the -camera, and images were
recorded at 1–5 min and 11⁄2, 3, 41⁄2, and 6 h after injection with a
single-head -camera (Orbiter; Siemens Medical Systems Inc.)
equipped with a parallel-hole, low-energy, all-purpose collimator.
Images were obtained with a 15% symmetric window over the
140-keV energy peak of 99mTc. After acquisition of 200,000–
300,000 counts, the images were digitally stored in a 256 	 256
matrix.
Scintigraphic images were analyzed quantitatively by drawing
regions of interest over the abscess and the uninfected contralateral
thigh muscle (background). Abscess-to-background ratios were
calculated.
After completion of the final imaging session (6 h after injec-
tion), all rabbits were killed with a lethal dose of pentobarbital
(Euthesate; Ceva Sante Animale). Samples of blood, infected thigh
muscle, uninfected contralateral thigh muscle, lung, spleen, liver,
kidneys, and intestines were collected. The dissected tissues were
weighed and counted in a -counter. To correct for radioactive
decay, injection standards were counted simultaneously. The mea-
sured activity in samples was expressed as the percentage of
injected dose per gram tissue (%ID/g). Abscess-to-contralateral
muscle ratios and abscess-to-blood ratios were calculated.
Using the same rabbit model of intramuscular infection, the
99mTc-labeled CXC chemokines CTAP-III, GCP-2, ENA-78, PF-4,
and IP-10 were tested for infection imaging in pilot experiments
using 2 rabbits per 99mTc-labeled CXC chemokine.
Statistical Analysis
All mean values are given as %ID/g, %ID, or ratios  1 SEM.
The data were analyzed statistically using the 1-way ANOVA with
the Dunnett posttest (GraphPad Instat 3.00 Win 95) comparing
data for the 99mTc-labeled NAP-2 derivatives with data for 99mTc-
labeled NAP-2.
RESULTS
99mTc Labeling of Chemokines
The radiochemical purities of 99mTc-labeled NAP-2, its
variants, and IL-8 exceeded 98% in all cases, as determined
by ITLC, excluding the need for further purification. This is
in line with our previous findings for IL-8, where the same
labeling strategy using tricine and nicotinic acid as coli-
gands was adopted (19). The specific activities of the prep-
arations of 99mTc-labeled NAP-2, its variants, and IL-8 were
high, approximately 40–50 MBq/g of protein. The specific
activities of the preparations of 99mTc-labeled CTAP-III,
GCP-2, ENA-78, PF-4, and IP-10 ranged from 20 to 40
MBq/g of protein.
Receptor-Binding Competition Assays
The receptor-binding competition assays involved a di-
rect comparison in binding to the CXCR2 receptor between
HYNIC-conjugated proteins—that is, chemically modified
proteins. The relative potencies of HYNIC-conjugated
NAP-2 and its 3 C-terminally truncated variants for binding
to CXCR2 receptors transfected on Jurkat cells are depicted
in Figure 1. A 2- to 3-fold higher binding potency was found
for the HYNIC-conjugated forms of NAP-2(1–68) and
NAP-2(1–63) as compared with NAP-2. HYNIC-conju-
gated NAP-2(1–66) showed a 10-fold higher binding po-
tency relative to NAP-2. For comparison, the binding po-
tency of HYNIC-conjugated IL-8 was 75-fold higher.
Animal Studies
Table 1 summarizes the biodistribution results of the 4
radiolabeled chemokine preparations in rabbits with an E.
coli infection at 6 h sfter injection. Figure 2 presents uptake
of the 4 radiolabeled chemokines in neutrophil-rich tis-
sues—that is, the abscess, the lungs, and the spleen. 99mTc-
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Labeled NAP-2(1–66) showed higher uptake in the abscess
(P  0.05) as compared with 99mTc-labeled NAP-2. Phys-
iologic uptake in the lungs was significantly higher for
99mTc-labeled NAP-2(1–66) as well (P  0.01). Abscess-
to-muscle and abscess-to-blood ratios showed no significant
differences. The agents cleared predominantly via the kid-
neys, and the residual amount of radioactivity in the kidneys
was significantly lower (P  0.01) for the 2 shortest labeled
NAP-2 variants, NAP-2(1–66) and NAP-2(1–63), as com-
pared with NAP-2. In comparison with 99mTc-labeled
NAP-2, IL-8 showed significantly higher uptake in the
abscess (0.39  0.09 %ID/g), the lungs (0.12  0.01
%ID/g), and the spleen (0.55  0.13 %ID/g) and higher
abscess-to-muscle ratios (215  90) and abscess-to-blood
ratios (24  4).
Figure 3 shows the scintigrams acquired between 0 and
6 h after injection of 99mTc-labeled NAP-2 and its 3
C-terminally truncated variants. -Camera imaging rapidly
visualized the abscess from a few hours after injection
onward for all preparations. Quantitative analysis of the
images revealed that the abscess-to-background ratios im-
proved with time for all labeled chemokines up to 9  1 for
NAP-2, 9  2 for NAP-2(1–68), 13  1 for NAP-2(1–66),
and 10  1 for NAP-2(1–63) at 6 h after injection. For
comparison, 99mTc-IL-8 generated an abscess-to-back-
ground ratio of 20  4 in the same animal model. Imme-
diately after injection, high kidney uptake was observed for
all preparations, remaining prominent throughout the study.
An overview of the various radiolabeled CXC chemo-
kines studied in the same rabbit model of intramuscular
infection is presented in Figure 4. Figure 4 contains repre-
sentative images of 99mTc-labeled IL-8 (high affinity for
FIGURE 1. Relative potencies of HYNIC-conjugated NAP-2
and 3 C-terminally truncated variants to compete with 99mTc-
labeled IL-8 for binding to Jurkat cells transfected with CXCR2
receptor. Potency of HYNIC-conjugated NAP-2 is set at 1.
TABLE 1
Biodistribution of 99mTc-Labeled NAP-2 and 3 C-Terminally Truncated Variants in Rabbits
with Escherichia coli–Induced Intramuscular Infection
Parameter 99mTc-NAP-2 99mTc-NAP-2(1–68) 99mTc-NAP-2(1–66) 99mTc-NAP-2(1–63)
Biodistribution
Blood 0.015  0.001 0.013  0.002 0.017  0.003 0.013  0.002
Muscle 0.0017  0.0002 0.0016  0.0002 0.0024  0.0001 0.0018  0.0003
Abscess 0.084  0.015 0.098  0.010 0.189  0.044 0.114  0.017
Lung 0.057  0.005 0.081  0.015 0.171  0.026 0.074  0.016
Spleen 0.15  0.02 0.20  0.05 0.30  0.06 0.17  0.03
Kidney 3.1  0.1 3.0  0.1 1.9  0.1 2.3  0.1
Liver 0.032  0.001 0.035  0.001 0.048  0.006 0.043  0.007
Intestine 0.011  0.001 0.012  0.001 0.016  0.002 0.014  0.001
Ratio
Abscess/muscle 52  11 65  11 80  23 66  14
Abscess/blood 5.7  1.3 8.0  1.1 12  3 8.8  1.2
Rabbits were injected with 20 MBq 99mTc-labeled chemokine, killed at 6 h after injection, and dissected. Tissue samples were weighed
and counted in a -counter. Values are expressed as %ID/g tissue  1 SEM or as ratios thereof.
FIGURE 2. Uptake of 99mTc-labeled NAP-2 and 3 C-terminally
truncated variants at 6 h after injection in tissues with high
natural abundancy of neutrophils: abscess, lungs, and spleen.
Values are expressed as %ID/g  1 SEM.
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both CXCR1 and CXCR2), CTAP-III (no binding to
CXCR2), NAP-2, and its variants (various affinities for
CXCR2), GCP-2 (acts via both CXCR1 and CXCR2), and
ENA-78 (high affinity for CXCR2). Two examples of ELR
CXC chemokines with poor neutrophil attractant capacity
and no binding to CXCR1 and CXCR2 are PF-4 and IP-10.
Figure 4 illustrates the good characteristics for infection
imaging of various 99mTc-labeled ELR CXC chemokines,
especially for NAP-2(1–66) and IL-8. In comparison with
abscess uptake of NAP-2(1–66) (0.189 %ID/g) and IL-8
(0.39 %ID/g), only modest uptake was found for GCP-2
(0.081 %ID/g) and ENA-78 (0.056 %ID/g), and low uptake
was found for CTAP-III (0.016 %ID/g), PF-4 (0.016 %ID/
g), and IP-10 (0.0052 %ID/g).
DISCUSSION
To select the most suitable candidate for infection imag-
ing within the family of CXC chemokines, we screened a
series of 99mTc-labeled CXC chemokines for infection im-
aging. In this study, we focused on the relationship between
binding affinity toward the CXCR2 receptor and suitability
for infection imaging in a selected group of CXC chemo-
kines: NAP-2 (70 residues) and 3 C-terminally truncated
variants: NAP-2(1–68), NAP-2(1–66), and NAP-2(1–63).
It was previously shown that limited and defined truncation
at the C-terminus of native NAP-2 enhances receptor bind-
ing and degranulation activity (15,16). A most prominent
increase in potency to stimulate neutrophil degranulation
and to bind neutrophils was observed for isoforms of NAP-2
with a C-terminal deletion of 4 amino acids (NAP-2(1–66))
and 7 amino acids (NAP-2(1–63)). Here, NAP-2 and its 3
variants were conjugated with the bifunctional chelator
HYNIC, which links 99mTc to protein via primary amino
groups within the protein. In receptor-binding competition
assays, the relative binding affinities of the HYNIC-conju-
gated (i.e., chemically modified) proteins were determined
and the highest binding potency for the CXCR2 receptor
was found for NAP-2(1–66). This finding correlated well
with the findings of the infection imaging experiments with
99mTc-labeled NAP-2 and its variants. 99mTc-Labeled NAP-
2(1–66) showed the highest uptake in the abscess and the
highest physiologic uptake in the lungs, an organ that ac-
commodates large numbers of neutrophils. HYNIC-conju-
gated IL-8 had a higher affinity for the CXCR2 receptor and
99mTc-labeled IL-8 displayed the highest uptake in the ab-
scess.
FIGURE 3. Images of rabbits with an E. coli–induced abscess
in left thigh muscle (right side on image) at 11⁄2, 3, 41⁄2, and 6 h
after injection of 99mTc-labeled NAP-2 and 3 C-terminally trun-
cated variants.
FIGURE 4. Overview of images of rab-
bits with E. coli–induced intramuscular in-
fection obtained 6 h after injection of vari-
ous 99mTc-labeled CXC chemokines. (A)
ELR CXC chemokines: IL-8, CTAP-III,
NAP-2 analogs, GCP-2, and ENA-78. (B)
ELR CXC chemokines: PF-4 and IP-10.
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A survey of the 99mTc-labeled CXC chemokines PF-4,
IP-10, CTAP-III, ENA-78, and GCP-2 in infection imaging
provided additional evidence for the close relationship be-
tween neutrophil-binding affinity and suitability for infec-
tion imaging. The presence of an ELR sequence within the
CXC chemokine was associated with effective imaging of
infection. The 99mTc-labeled non-ELR CXC chemokines
reported in this article, PF-4 and IP-10, lack significant
binding to the CXCR1 and the CXCR2 receptor (10,11) and
showed a very low uptake in the abscess. The presence of an
ELR sequence may be a prerequisite but does not guarantee
effective infection imaging. The radiolabeled ELR CXC
chemokine CTAP-III showed very low uptake in the ab-
scess as well. CTAP-III is an N-terminally extended pre-
cursor of NAP-2. CTAP-III neither binds to or activates
neutrophils in sharp contrast to NAP-2. NAP-2 has 1 amino
acid residue preceding the ELR sequence and CTAP-III has
16 residues preceding the ELR sequence. It is suggested that
the fraying N-terminal end of CTAP-III is interfering with
the binding (23). In this way, the ELR sequence is masked
and functionally not present. The radiolabeled ELR CXC
chemokines ENA-78 and GCP-2 showed only a modest
uptake in the abscess. ENA-78 has high affinity toward the
CXCR2 receptor only, but this affinity was found to be
lower than that of GCP-2 and considerably lower than that
of IL-8. GCP-2 is reported to be efficient in binding the
CXCR1 receptor as well (9). In the present study, 99mTc-
labeled GCP-2 more clearly delineated infectious foci than
ENA-78.
In accordance with these findings are the findings of a
comparative study in imaging infection using 99mTc-labeled
C5a and C5a des Arg74 (C5adR) (24). The complement
anaphylatoxin C5a (74 amino acids) differs from its natural
metabolite C5adR in just 1 additional C-terminal amino acid
residue for C5a. Both act on a common receptor on different
cell types, including neutrophils and monocytes. The recep-
tor-binding affinity of C5a exceeds that of C5adR by 1–2
orders of magnitude. For infection imaging, 99mTc-labeled
C5a showed much better characteristics than C5adR: Up-
take in the abscess was 5-fold higher for C5a than for
C5adR (24).
The importance of the C-terminal domain in the function
of CXC chemokines was illustrated in this study by radio-
labeled NAP-2 and 3 C-terminally truncated isoforms. Dif-
ferences in biologic (and scintigraphic) behavior are attrib-
uted to the physicochemical properties of the deleted
residues (16). Full-size NAP-2 bears 3 acidic amino acids in
the C-terminal end: D66, E67, and D70. The loss of particu-
larly the acidic residues D70 and E67 caused subsequent
increases in biologic activity and binding to neutrophils, and
the loss of a third acidic residue in NAP-2 resulted in
NAP-2(1–63), the most active NAP-2 isoform. Further de-
letion of the C-terminal L63 was associated with a 3-fold
reduction of the capacity of NAP-2(1–63) to bind to and
activate neutrophils (16). Apparently, L63 is a functionally
important residue within the structure of NAP-2. The
present study showed a discrepancy with these reported
findings: Here, the most suitable NAP-2 derivative for in-
fection imaging was radiolabeled NAP-2(1–66), not NAP-
2(1–63). This difference might be ascribed to the diverse
effects of chemical modification on receptor binding. The
chemokines were labeled with 99mTc using an S-HYNIC
derivative as bifunctional agent. S-HYNIC is reacted with
primary amino groups—that is, the -amino group of the
N-terminal amino acid residue or the -amino group of
lysine residues within the protein. The conjugation of S-
HYNIC might interfere with receptor binding. It is tempting
to speculate that the fraying C-terminal end of NAP-2(1–
66) might prevent effective reaction of S-HYNIC with the
lysines at critical positions 61 and 62 near to L63. This might
explain the preferential qualities for infection imaging of
99mTc-labeled NAP-2(1–66) as compared with NAP-2(1–63).
The importance of the N-terminal domain in the function
of the CXC chemokines is exemplified in the pair of closely
related proteins CTAP-III and NAP-2 in our study and also
in a comparison between 2 naturally existent isoforms of
IL-8 (2). The most abundant form of naturally occurring
IL-8 is 72 amino acids long. This form has 3 residues in
front of the ELR sequence. A 77-amino-acid variant of IL-8
is produced by endothelial cells and is extended at the
N-terminus by 5 amino acids. The longer protein is some
10-fold less potent than the shorter protein in attracting and
activating neutrophils. The differences might, again, be
attributed to the negative interference of the longer fraying
N-terminal end of IL-8(77) in the binding of the protein to
CXC receptors. IL-8(72) has a high affinity for both the
CXCR1 and the CXCR2 receptor, and its potency as a
neutrophil chemoattractant has been estimated to be 3-fold
higher than that of NAP-2 (25). The potential of radiola-
beled IL-8(72) for imaging infection has been extensively
explored by us (18–20) and, not surprisingly, is superior to
that of other CXC chemokines, including the NAP-2 ana-
logs.
CONCLUSION
This study showed a clear relationship between affinity to
receptors on neutrophils and suitability for infection imag-
ing. Of the NAP-2 variants, NAP-2(1–66) combined high-
est affinity to CXCR2 with best characteristics for imaging.
IL-8, having a clearly higher affinity for the CXCR1 and
CXCR2 receptor than for NAP-2(1–66), showed a superior
imaging quality. The other CXC chemokines tested ap-
peared to be less suitable for infection imaging.
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